Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Macrophages secrete matrix metalloproteinase 9 (MMP-9), an enzyme that weakens the fibrous cap of atherosclerotic plaques, predisposing them to plaque rupture and subsequent ischemic events. Recent work indicates that statins strongly reduce the possibility of heart attack. Furthermore, these compounds appear to exert beneficial effects not only by lowering plasma low-density-lipoprotein cholesterol but also by directly affecting the artery wall. To evaluate whether statins influence the proinflammatory responses of monocytic cells, we studied their effects on the chemotactic migration and MMP-9 secretion of human monocytic cell line THP-1. Simvastatin dose dependently inhibited THP-1 cell migration mediated by monocyte chemoattractant protein 1, with a 50% inhibitory concentration of about 50 nM. It also inhibited bacterial lipopolysaccharide-stimulated secretion of MMP-9. The effects of simvastatin were completely reversed by mevalonate and its derivatives, farnesylpyrophosphate and geranylgeranyl pyrophosphate, but not by ubiquinone. Additional studies revealed similar but more profound inhibitory effects with L-839,867, a specific inhibitor of geranylgeranyl transferase. However, α-hydroxyfarnesyl phosphonic acid, an inhibitor of farnesyl transferase, had no effect. C3 exoenzyme, a specific inhibitor of the prenylated small signaling Rho proteins, mimicked the inhibitory effects of simvastatin and L-839,867. These data supported the role of geranylgeranylation in the migration and MMP-9 secretion of monocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · cited 1×
“Such agents improve the survival of patients with coronary heart disease in hypercholesterolemic individuals [1, 2 ]. Although the benefits of statins are primarily attributed to their lipid-lowering effects, accumulating evidence suggests the possibility of other beneficial effects independent from serum cholesterol…”
BackgroundRegulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“Some of these intermediates, such as farnesylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), are substrates for the posttranslational isoprenylation of various proteins involved in cell signaling [ 6 , 7]. Results from several recent studies indicated that some of the direct effects of HMG-CoA reductase i…”
BackgroundPost-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · cited 2×
“It was found that the statin affects nitric oxide synthase expression [ 8 ], fibrinolytic activity [9], apoptosis [10], and plasminogen activator inhibitor-1 expression [18], and that all these may be linked to protein geranylgeranylation.”
Background
Cited by
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,097
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1839 · Cited by 683
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Luan, Z., Chase, A. J., & Newby, A. C. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000068646.76823.ae · Cited by 341
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
Simvastatin Inhibits Cigarette Smoking–induced Emphysema and Pulmonary Hypertension in Rat Lungs
Lee, J.-H., Lee, D.-S., Kim, E.-K., Choe, K.-H., Oh, Y.-M., Shim, T.-S., Kim, S.-E., Lee, Y.-S., & Lee, S.-D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-041oc · Cited by 257
Daub, K., Langer, H., Seizer, P., Stellos, K., May, A. E., Goyal, P., Bigalke, B., Schönberger, T., Geisler, T., Siegel‐Axel, D., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6265fje · Cited by 207
Coenzyme Q10 and statins: Biochemical and clinical implications
Littarru, G. P., & Langsjoen, P. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.002 · Cited by 188
Katsuki, S., Matoba, T., Nakashiro, S., Sato, K., Koga, J.-I., Nakano, K., Nakano, Y., Egusa, S., Sunagawa, K., & Egashira, K. (2014) · Circulation · doi:10.1161/circulationaha.113.002870 · Cited by 179
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Metadata
- Authors
- Wong, B., Lumma, W. C., Smith, A. M., Sisko, J. T., Wright, S. D., & Cai, T.-Q.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-06-01
- Volume
- 69
- Issue
- 6
- Pages
- 959-962
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2114553294
- Cited by
- 156
- References
- 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.